We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Mitochondrial ToxGlo™ Assay

G8000

A Cell-Based Method for Predicting Potential Mitochondrial Dysfunction

  • Distinguish primary mitochondrial dysfunction from secondary cytotoxic events
  • Predictive for mitochondrial toxicities
  • Fast, cost-effective and easy to implement

Size

Catalog number selected: G8000

$ 215.00 Your price: Log in

Add to Helix Add to Helix
Mitochondrial ToxGlo™ Assay
10ml
$ 215.00
Your price: Log in
Change Configuration

Predictive Data to Distinguish Mitochondrial Dysfunction

The Mitochondrial ToxGlo™ Assay is a cell-based assay method that employs a sequential addition, multiplexed assay chemistry for predicting potential mitochondrial dysfunction as a result of xenobiotic exposure. The assay is based on the differential measurement of biomarkers associated with changes in cell membrane integrity and cellular ATP levels relative to vehicle-treated control cells during short exposure periods. Cell membrane integrity is first assessed by measuring the presence or absence of a distinct protease activity associated with necrosis using a fluorogenic peptide substrate (bis-AAF-R110) to measure "dead cell protease activity". The bis-AAF-R110 substrate cannot cross the intact membrane of live cells and therefore gives no signal with viable cells. Next, ATP is measured by adding an ATP detection reagent, resulting in cell lysis and generation of a luminescent signal proportional to the amount of ATP present. The two sets of data can be combined to produce profiles representative of mitochondrial dysfunction or non-mitochondrial related cytotoxic mechanisms.

Mammalian cells generate ATP by mitochondrial (oxidative phosphorylation) and non-mitochondrial (glycolysis) methods. To achieve optimal mitochondrial responsiveness, it may be necessary to refine cell culture conditions. Replacing glucose-supplemented medium with galactose-containing medium may increase cellular oxygen consumption and augment mitochondrial susceptibility to mitotoxicants.

Mitochondrial Responsiveness to a Model Toxin in the Presence of Galactose or Glucose

9954MA-W

Some cells treated in the presence of glucose may preferentially rely on glycolysis to meet bioenergetic needs and are therefore relatively unresponsive to mitochondrial toxins (Glucose ATP). Cells treated in the presence of galactose must use oxidative phosphorylation to generate ATP and are therefore more responsive to mitochondrial perturbation (Galactose ATP). Oligomycin treatment did not cause changes in membrane integrity in either formulation of medium (Galactose Cytotoxicity and Glucose Cytotoxicity). Shown are data from K562 cells at 10,000 cells/well in a white Costar® 96-well plate. The cells were exposed to oligomycin for 2 hours.


Mitochondrial ToxGlo™ Assay produces profiles that are consistent with mitochondrial toxicity and discernible from other non-mitotoxic mechanisms of cell death. The assay is easy to implement as it uses a simple sequential “add-mix-read” format, and assays are performed directly in cell culture plates using standard multimode detection instrumentation.

A flexible and easily automated assay, the volume of reagent addition can be scaled to meet throughput needs; the assay is amenable to automation in 96- and 384-well plates.

Representative Profiles of Mitochondrial Toxicity

9955MA-W-a
9955MA-W-b
9955MA-W-c
9955MA-W-d

K562 cells were plated at 10,000 cells/well in white 96-well plates (Costar®) and treated with serial dilutions of compounds resuspended in glucose-free (galactose-supplemented) RPMI 1640 media for 2 hours. Panel A. The changes in ATP or membrane integrity (MI) are detected, which indicates that the compound is not a mitochondrial toxin. Panel B. The reduction in ATP with commensurate MI changes indicate that the compound is not a mitochondrial toxin; instead primary necrosis is taking place. Panel C. The reduction in ATP with no changes in MI indicates that the compound is a mitochondrial toxin. Panel D. The reduction in ATP with discordant changes in MI indicate that the compound is a mitochondrial toxin.

Simple, "Add-Mix-Measure" Protocol

"Add-mix-measure" protocol is fast and easy to implement. No parallel processing in glucose-containing medium.

14281MA-W

Specifications

You are viewing: G8000 Change Configuration

What's in the box?

Item Part # Size

bis-AAF-R110 Substrate

G609A 1 × 10μl

Assay Buffer

G610A 1 × 10ml

ATP Detection Buffer

G806A 1 × 10ml

ATP Detection Substrate

V363A 1 × 1 vial

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Specifications

You are viewing: G8001 Change Configuration

What's in the box?

Item Part # Size

bis-AAF-R110 Substrate

G609B 2 × 50μl

Assay Buffer

G610B 1 × 50ml

ATP Detection Buffer

G806B 1 × 100ml

ATP Detection Substrate

V363B 1 × 1 vial

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

workflow-background
Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom